📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-20 21:52
136 analysed today
FollowTelegram
136
Today
149,537
All-time analysed
42,893
Positive
6,653
Negative
91,318
Neutral
8,605
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
9 announcements match the current filters (relevance ≥ 5).
Dolphin Medical Calls Board Meeting on Sept 21 to Appoint New Chairman & Promoter
Dolphin Medical Services Ltd has scheduled a Board Meeting for September 21, 2026, to consider appointing Mr. Amarandhar Reddy Kotha as Chairman and Promoter Director. The Board will also evaluate reclassifying Director Rajesh Kumar Mallour from Professional to Promoter category, along with committee reconstitutions. Additionally, the filing mentions filings related to the reclassification of the Promoter Group post completion of applicable open offer compliances. This signals potential management and control restructuring for a micro-cap company with a market cap of approximately Rs 2 Cr.
Confidence: HIGH
What changedDolphin Medical has initiated board procedures to induct a new Chairman and Promoter Director and reclassify internal leadership into the Promoter Group.
Why it mattersManagement transitions and promoter reclassifications tied to open offer compliances indicate a potential change of control or strategic pivot for this micro-cap firm (TTM revenue ~Rs 1 Cr).
Meeting date: 21st September, 2026Meeting time: 11:00 A.M.Market cap: Rs 2 CrTTM Revenue: Rs 1 Cr
📅 Short termMarket may react to leadership changes and potential clarity regarding open offer proceedings following the board outcome.
📈 Long termA shift in promoter leadership could determine whether the company revitalizes its micro-scale healthcare services business.
⚠ Risk flags
- Open offer compliance completion and regulatory approvals required
- Extremely low liquidity and micro-cap scale (market cap ~Rs 2 Cr)
- Execution uncertainty regarding incoming leadership plans
Key Highlights
Board meeting scheduled for Monday, September 21, 2026 at 11:00 AM
Proposal to appoint Mr. Amarandhar Reddy Kotha (DIN: 07425226) as Chairman and Promoter Director
Proposal to change category of Mr. Rajesh Kumar Mallour to Promoter from Professional
Reclassification of Promoter Group subject to completion of applicable open offer compliances
👀 What to Watch
Track the outcomes of the September 21, 2026 board meeting and watch for regulatory disclosures regarding open offer compliances and ownership restructuring.
Acquirers Conclude Open Offer for Dolphin Medical Services with 21.08% Post-Offer Stake
Rarever Financial Advisors has released the post-offer advertisement regarding the open offer for Dolphin Medical Services Ltd by Mr. Amarandhar Reddy Kotha and Mr. Mallour Rajesh Kumar. Against an offer size of 39,25,988 shares (26.00%) at ₹4.80 per share, only 18,000 shares (0.12%) were tendered and accepted. Combined with 31,63,390 shares (20.95%) acquired via Share Purchase Agreement (SPA), the acquirers now hold 31,82,717 equity shares, representing 21.08% of total equity share capital.
Confidence: HIGH
What changedAcquirers finalized the takeover process under SEBI (SAST) Regulations, consolidating a 21.08% direct equity holding in the target company.
Why it mattersThe low tendering in the open offer (0.12%) was driven by market price (₹7.0) trading above the offer price (₹4.80), concluding the change of control process without significant public float absorption.
Open Offer Price: ₹4.80Shares Tendered & Accepted: 18,000 (0.12%)Shares via SPA: 31,63,390 (20.95%)Acquirers Post-Offer Stake: 31,82,717 (21.08%)Total Promoter Group Stake: 26.57%
📅 Short termNeutral to procedural; clears regulatory completion of the takeover process without price distortion.
📈 Long termDepends on the new promoters' strategic vision and operational revival plans for the micro-cap healthcare business.
⚠ Risk flags
- Extremely small revenue base (TTM ~₹1 Cr) and micro-cap liquidity risks
- Low promoter holding (26.57% total promoter group)
Key Highlights
Open offer completed at ₹4.80 per share against an offer size of 39,25,988 shares (26.00%).
Only 18,000 shares (0.12%) tendered and accepted, resulting in total offer payout of ₹86,400.
SPA acquisition accounted for 31,63,390 shares (20.95% of equity capital).
Post-offer, total promoter & promoter group holding stands at 26.57% (Acquirers: 21.08%, Existing Promoters: 5.49%).
👀 What to Watch
Watch for subsequent management/board restructuring disclosures and strategic updates on business operations following the completion of the acquisition.
Dolphin Medical Q1 PAT Drops 43% YoY to Rs 1.78 Lakh; Revenue Up 22% to Rs 20.60 Lakh
Dolphin Medical Services reported a 22.2% YoY growth in revenue from operations to Rs 20.60 lakh for Q1 FY27 compared to Rs 16.86 lakh in Q1 FY26. However, net profit fell 43.1% YoY to Rs 1.78 lakh from Rs 3.13 lakh in Q1 FY26 due to higher operational and employee expenses. On a sequential basis, revenue grew 7.3% from Rs 19.20 lakh in Q4 FY26, with net profit rising from Rs 0.71 lakh. The company continues to operate at a micro scale with TTM turnover hovering around Rs 1 crore.
Confidence: HIGH
What changedDolphin Medical Services reported its Q1 FY27 results, recording modest revenue expansion alongside lower YoY profit due to higher operating expenses.
Why it mattersGiven the nano-cap size (market cap ~Rs 10 crore) and low revenue base (~Rs 0.75-1.0 crore annually), minor shifts in operational expenses significantly impact quarterly profitability.
Revenue from Operations: 20.60 LakhsNet Profit: 1.78 LakhsTotal Expenses: 19.74 LakhsBasic EPS: 0.11
📅 Short termMuted impact expected as financial results reflect regular quarterly performance at a very small base.
📈 Long termLimited structural impact unless the company scales its core diagnostic or healthcare service offerings significantly.
⚠ Risk flags
- Micro-scale operations (<Rs 1 cr annual turnover)
- Low promoter holding at 26.44%
- Elevated valuation relative to earnings base (P/E ~150x)
Key Highlights
Revenue from operations grew 22.2% YoY to Rs 20.60 lakh vs Rs 16.86 lakh in Q1 FY26
Net profit stood at Rs 1.78 lakh, down 43.1% YoY from Rs 3.13 lakh but up from Rs 0.71 lakh in Q4 FY26
Total expenses rose 34.7% YoY to Rs 19.74 lakh, driven by higher materials consumed (Rs 3.50 lakh) and employee costs (Rs 4.70 lakh)
Reported EPS for the quarter was Rs 0.11 compared to Rs 0.02 in Q1 FY26
Promoter holding remained constant at 26.44% with zero pledged shares
👀 What to Watch
Monitor whether the company can achieve meaningful operational scale beyond sub-Rs 25 lakh quarterly revenues to sustainably expand margins.
Dolphin Medical Q1 FY27 Revenue at ₹20.60 Lakh, Net Profit Down 43% YoY to ₹1.78 Lakh
Dolphin Medical Services reported a 22.2% YoY growth in revenue from operations to ₹20.60 lakh for the quarter ended June 30, 2026, up from ₹16.86 lakh in Q1 FY26. Net profit fell 43.1% YoY to ₹1.78 lakh compared to ₹3.13 lakh in the prior-year period, pressured by higher employee and material expenses. Sequentially, net profit improved from ₹0.71 lakh in Q4 FY26. Total expenses for the quarter expanded 34.7% YoY to ₹19.74 lakh.
Confidence: HIGH
What changedDolphin Medical reported its unaudited financial results for the first quarter ended June 30, 2026.
Why it mattersDemonstrates ongoing marginal profitability, but high cost growth relative to revenue keeps absolute operating earnings constrained.
Revenue from Operations: ₹20.60 LakhsNet Profit: ₹1.78 LakhsTotal Expenses: ₹19.74 LakhsOther Income: ₹0.92 LakhsPaid-up Equity Capital: ₹1509.99 Lakhs
📅 Short termSubdued impact expected given the micro-scale revenue and profit base.
📈 Long termLimited operational scale; accumulated negative reserves (₹-501.85 lakh as of FY26) highlight structural growth constraints.
⚠ Risk flags
- Extremely small quarterly revenue base (<₹0.25 Cr)
- Negative retained earnings/reserves (₹-501.85 Lakhs)
- Relatively low promoter holding of 26.44%
Key Highlights
Revenue from operations rose 22.2% YoY to ₹20.60 lakh (vs ₹16.86 lakh in Q1 FY26)
Net profit dropped 43.1% YoY to ₹1.78 lakh from ₹3.13 lakh in Q1 FY26, though up QoQ from ₹0.71 lakh
Total expenses rose 34.7% YoY to ₹19.74 lakh from ₹14.65 lakh
Total income including other income stood at ₹21.52 lakh vs ₹17.78 lakh YoY
👀 What to Watch
Monitor whether the company can meaningfully expand its commercial operations beyond the current micro-revenue scale (~₹0.20 crore quarterly run-rate).
₹4.80 Open Offer for 26% Stake in Dolphin Medical Services to Open July 31, 2026
Mr. Amarandhar Reddy Kotha and Mr. Mallour Rajesh Kumar are launching an open offer to acquire 39,25,988 equity shares, representing 26% of Dolphin Medical Services. The offer price is set at ₹4.80 per share, which is a significant discount to the current market price of ₹7.5. The tendering period will run from July 31, 2026, to August 13, 2026. The Committee of Independent Directors has recommended the offer as fair and reasonable per SEBI regulations.
Confidence: HIGH
What changedThe company has finalized the schedule and issued the pre-offer advertisement for a 26% stake acquisition by two individual acquirers.
Why it mattersFor a micro-cap company with only ₹1 Cr in TTM revenue, a change in control or a significant new stake by acquirers is a major corporate event that could dictate future business direction.
Offer Price: ₹4.80Current Market Price: ₹7.5Offer Size (Shares): 39,25,988Stake Offered: 26.00%Offer Opening Date: July 31, 2026Offer Closing Date: August 13, 2026
📅 Short termThe stock may see volatility as the open offer period begins, though the low offer price relative to market price suggests limited participation from public shareholders.
📈 Long termThe long-term outlook depends entirely on the new acquirers' ability to scale operations, as the company currently generates negligible profits and revenue.
⚠ Risk flags
- Offer price is at a deep discount to market price
- Extremely low revenue base (₹1 Cr TTM)
- Potential for low liquidity in a ₹10 Cr market cap stock
Key Highlights
Open offer to acquire 39,25,988 equity shares representing 26% of the voting capital
Offer price fixed at ₹4.80 per share, payable in cash
Tendering period scheduled from July 31, 2026, to August 13, 2026
Acquirers' total shareholding post-offer will be capped at 75% to maintain minimum public shareholding
Offer price of ₹4.80 is approximately 36% below the current market price of ₹7.5
👀 What to Watch
Investors should note the offer price is significantly below the current market price, making tendering unattractive at current levels. Watch for the completion of the offer and any subsequent management changes or business strategy shifts by the new acquirers.
26% Open Offer at ₹4.80 per share by new Acquirers for Dolphin Medical Services
Mr. Amarandhar Reddy Kotha and Mr. Mallour Rajesh Kumar have issued a formal Letter of Offer to acquire up to 39,25,988 equity shares (26% stake) of Dolphin Medical Services. The offer price is set at ₹4.80 per share, which represents a significant discount of approximately 39% compared to the current market price of ₹7.9. The tendering period is scheduled to open on July 31, 2026, and close on August 13, 2026. This move follows a potential change in control or substantial acquisition under SEBI (SAST) Regulations for this micro-cap healthcare provider.
Confidence: HIGH
What changedThe acquisition process has moved to the formal Letter of Offer stage, providing a concrete timeline for the 26% stake acquisition by new individual acquirers.
Why it mattersFor a company with only ₹1 Cr in TTM revenue and a ₹11 Cr market cap, a change in control or a 26% stake shift is highly material and could lead to a change in business direction or management.
Offer Price: ₹4.80Current Market Price: ₹7.9Offer Size (%): 26.00%Total Offer Value: ₹1.88 CrOffer Value vs Market Cap: 17.1%
📅 Short termThe stock may experience volatility as the market reacts to the low offer price relative to the current trading price. Retail participation in the open offer is expected to be low unless the market price drops significantly.
📈 Long termThe long-term impact depends on the strategic intent of the new acquirers for this micro-cap entity, which currently has stagnant revenues and minimal profitability.
⚠ Risk flags
- Offer price is at a ~39% discount to market price
- Extremely low liquidity in the stock
- Company has very small operational scale (₹1 Cr annual revenue)
Key Highlights
Open offer to acquire 39,25,988 equity shares representing 26.00% of the voting capital
Offer price fixed at ₹4.80 per share, significantly below the current market price of ₹7.9
Tendering period scheduled from July 31, 2026, to August 13, 2026
Total potential outlay for the offer is approximately ₹1.88 Cr based on the offer price
Identified date for determining eligible public shareholders was July 17, 2026
👀 What to Watch
Investors should note the significant gap between the offer price (₹4.80) and the market price (₹7.9), which makes tendering shares unattractive at current levels. Watch for the Independent Directors' recommendation due on July 29, 2026, and any potential upward revision of the offer price before July 30, 2026.
Resignation of CFO and Company Secretary Vaishnavi Sharma effective July 24, 2026
Dolphin Medical Services Ltd has announced the resignation of Ms. Vaishnavi Sharma from the dual roles of Chief Financial Officer (CFO) and Company Secretary (CS) cum Compliance Officer. The resignation was accepted by the Board on July 25, 2026, with the cessation effective from July 24, 2026. For a micro-cap company with a market capitalization of just ₹11 Cr and TTM revenue of ₹1 Cr, the exit of a key management person (KMP) handling both finance and compliance is a notable event. The company has not yet announced a successor for these statutory positions.
Confidence: HIGH
What changedThe company's Chief Financial Officer and Company Secretary has resigned, leaving two key statutory positions vacant.
Why it mattersIn micro-cap companies, KMPs often manage multiple critical functions; a vacancy in both finance and compliance roles can impact the timeliness and quality of financial disclosures.
Effective Date of Cessation: 24th July, 2026Market Capitalization: ₹11 CrTTM Revenue: ₹1 CrPromoter Holding: 26.44%
📅 Short termThe stock may see neutral to slightly cautious sentiment until a replacement is named, given the importance of the CFO role in financial reporting.
📈 Long termLimited structural impact if a qualified successor is appointed promptly; however, frequent management changes in small-cap firms can be a red flag.
⚠ Risk flags
- Vacancy in key statutory positions (CFO and CS)
- Small scale of operations (₹1 Cr revenue)
- Low promoter holding (26.44%)
Key Highlights
Resignation of Ms. Vaishnavi Sharma from the posts of CFO and Company Secretary effective July 24, 2026
Board meeting for approval conducted on July 25, 2026, between 4:30 P.M. and 5:00 P.M.
Company operates at a small scale with TTM revenue of only ₹1 Cr
Promoter holding remains constant at 26.44% as of June 2026
Market capitalization of the company is approximately ₹11 Cr
👀 What to Watch
Investors should monitor the company's next filing for the appointment of a new CFO and Compliance Officer to ensure there are no lapses in regulatory reporting or financial oversight.
Resignation of Company Secretary and CFO Vaishnavi Sharma Effective July 24, 2026
Dolphin Medical Services has announced the resignation of Vaishnavi Sharma from the dual roles of Company Secretary cum Compliance Officer and Chief Financial Officer (CFO). The resignation was accepted by the Board on July 25, 2026, with the cessation effective from July 24, 2026. This is a significant leadership change for a micro-cap company with a market capitalization of only ₹11 Cr and TTM revenue of ₹1 Cr. Investors should monitor the appointment of a successor to ensure continuity in regulatory compliance and financial oversight.
Confidence: HIGH
What changedThe company's primary officer responsible for both financial management (CFO) and regulatory compliance (CS) has resigned.
Why it mattersIn micro-cap companies, the CFO and CS are critical for maintaining governance and transparency; a simultaneous vacancy in these roles can disrupt financial reporting and investor relations.
Market Capitalization: ₹11 CrTTM Revenue: ₹1 CrEffective Date of Resignation: July 24, 2026Promoter Holding: 26.44%
📅 Short termThe stock may see some volatility or caution as the market reacts to the exit of the key person handling finance and compliance.
📈 Long termLimited structural impact if a qualified replacement is appointed promptly, though frequent management changes in micro-caps are generally viewed unfavorably.
⚠ Risk flags
- Simultaneous exit of CFO and Compliance Officer
- Micro-cap governance risk
- Low promoter holding (26.4%)
Key Highlights
Resignation of the individual holding three key roles: CS, Compliance Officer, and CFO.
Cessation of office effective from the close of business hours on July 24, 2026.
Board meeting for approval conducted on July 25, 2026, lasting 30 minutes (4:30 PM to 5:00 PM).
Company operates on a very small scale with TTM revenue of just ₹1 Cr and PAT of ₹0 Cr.
Promoter holding remains stagnant at 26.44% as of June 2026.
👀 What to Watch
Monitor the exchange filings for the appointment of a new CFO and Company Secretary to ensure the company maintains its listing compliance and financial reporting standards.
26% Open Offer at ₹4.80: Dolphin Medical Sets July 17 as Identified Date for Shareholder List
Dolphin Medical Services is undergoing a change in control with an open offer by Mr. Amarandhar Reddy Kotha and Mr. Mallour Rajesh Kumar to acquire up to 39,25,988 shares (26% stake). The offer price is fixed at ₹4.80 per share, which is a significant ~41% discount to the current market price of ₹8.2. The company has now fixed July 17, 2026, as the 'Identified Date' to determine the shareholders who will receive the formal Letter of Offer. This is a procedural step in the takeover process initiated in May 2026.
Confidence: HIGH
What changedThe company has finalized the specific date (July 17, 2026) to identify shareholders for the dispatch of the formal open offer document.
Why it mattersThis confirms the takeover process is moving forward, which will eventually lead to a change in the company's promoter group and management direction.
Offer Price: ₹4.80Offer Size (Shares): 39,25,988Voting Share Capital %: 26.00%Identified Date: July 17, 2026Current Market Price: ₹8.2
📅 Short termNeutral; the stock may see limited reaction as the offer price is not attractive for retail tendering compared to market rates.
📈 Long termThe long-term outlook depends on the new acquirers' ability to turnaround or scale the healthcare service business post-acquisition.
⚠ Risk flags
- Offer price is at a ~41% discount to market price
- Potential for low liquidity if the new promoters consolidate a large stake
Key Highlights
Open offer for 39,25,988 fully paid-up equity shares representing 26.00% of voting capital
Offer price set at ₹4.80 per share, compared to the current market price of ₹8.2
Identified date for determining eligible shareholders fixed as July 17, 2026
Acquisition led by two individual acquirers: Mr. Amarandhar Reddy Kotha and Mr. Mallour Rajesh Kumar
Process managed by Rarever Financial Advisors Private Limited
👀 What to Watch
Monitor the dispatch of the Letter of Offer and the subsequent announcement of the tendering period; however, note that the offer price is significantly below the current market price.
